Product Details:
| Minimum Order Quantity | 10 Bottle |
| Manufactured By | NEOGENE B |
| Generic Name | LENALIDOMIDE |
| Country of Origin | Made in India |
| STRENGHTH | 10 MG , 15MG AND 25 MG |
| FORMULATION | TABLET |
| SUBSTITUE | YES AVAILABLE |
lenalidomide (Rx) Brand and Other Names: Revlimid Classes: Antineoplastics, Angiogenesis Inhibitors Dosing & Uses Adult Pediatric Dosage Forms & Strengths capsule (Revlimid, generic) 2.5mg 5mg 10mg 15mg 20mg 25mg Myelodysplastic Syndromes Indicated for transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes (MDS) associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities 10 mg PO qDay; treatment is modified based upon clinical and laboratory findings Continue treatment until disease progression or unacceptable toxicity Multiple Myeloma Treatment Indicated in combination with dexamethasone for treatment of multiple myeloma (MM) 25 mg PO qDay on Days 1-21 of repeated 28-day cycles (use with dexamethasone) Ineligible for auto-HSCT: Continue until disease progression or unacceptable toxicity Dexamethasone schedule 40 mg PO qDay on Days 1-4, 9-12, and 17-20 of each 28-day cycle for first 4 cycles, THEN 40 mg PO qDay on Days 1-4 every 28 days Age >75 yr: 20 mg PO qDay on Days 1, 8, 15, and 22 of each 28-day cycle Maintenance Indicated as maintenance therapy for MM following autologous hematopoietic stem cell transplantation (auto-HSCT) 03/10/2023, 17:35 Revlimid (lenalidomide) dosing, indications, interactions, adverse effects, and more https://reference.medscape.com/drug/revlimid-lenalidomide-342200 2/6 Initiate after adequate hematologic recovery (ie, ANC ≥1000/mcL and/or platelet counts ≥75,000/mcL) Starting dose: 10 mg PO qDay continuously (ie, Day 1-28 of repeated 28-day cycles) until disease progression or unacceptable toxicity After 3 cycles: May increase dose to 15 mg PO qDay if tolerated Hematopoietic stem cell mobilization should occur within 4 cycles of a lenalidomidecontaining therapy Mantle Cell Lymphoma Indicated for MCL in patients whose disease has relapsed or progressed after 2 prior therapies, 1 of which included bortezomib 25 mg PO qDay on Days 1-21 of repeated 28-day cycles; treatment is modified based on clinical or laboratory findings Continue until disease progression or unacceptable toxicity
Additional Information:
- Production Capacity: 1000
- Delivery Time: 10 DAYS
- Packaging Details: BOX
